Former Louisiana Attorney General, Charles C. Foti, Jr., is leading an investigation into Hims & Hers Health, Inc. This comes after a troubling decision by Novo Nordisk to end its partnership with the company. In June 2025, Novo Nordisk claimed Hims had violated laws by selling compounded drugs under misleading pretenses. They raised concerns about the safety of these drugs, citing potential harmful ingredients.
Following these events, Hims & Hers and its executives faced a securities class action lawsuit. The lawsuit alleges that they did not share key information with investors, particularly regarding operations and the status of their relationship with Novo Nordisk. Recently, a court granted permission for this case to proceed, rejecting Hims’ attempt to dismiss it.
The focus of Kahn Swick & Foti’s (KSF) investigation is whether Hims & Hers’ leadership accurately represented the company to its shareholders or breached any laws in the process.
Expert Insight: Legal experts emphasize the importance of transparency in business relationships. Michael Decker, a securities law professor, states, “Companies must be honest about risks. This avoids legal issues and maintains trust with investors.” Trust is pivotal in restoring confidence in companies like Hims & Hers, especially given the current scrutiny.
Recent Trends: On social media, there has been significant discussion about telehealth practices. Users are increasingly concerned about the safety and regulation of online health services. Many have voiced skepticism about companies that sell medications without in-depth consultation.
Looking at Statistics: According to a recent survey by Health Affairs, nearly 40% of Americans have hesitations about telehealth services, particularly regarding safety and efficacy. This finding underscores why transparency is critical for telehealth companies as they navigate a challenging regulatory landscape.
For more information on KSF and their work, visit Kahn Swick & Foti’s website.
